A 37-year-old woman with ER+/HER2-low breast cancer participating in the NCT01918254 clinical trial [41] and treated with the combination of lumretuzumab plus pertuzumab was selected for a detailed analyses in a case study. Here, ERBB2 is linked to breast carcinoma.